David Piacquad - Amgen Insider

Amgen Inc -- USA Stock  

USD 186.11  0.18  0.10%

Senior Vice President - Business Development

Mr. David A. Piacquad is the Senior Vice President Business Development of Amgen Inc. Mr. Piacquad joined the Company in June 2010 and, until January 2014, served as Vice President, Strategy and Corporationrationrate Development. From January 2014 to March 2014, Mr. Piacquad served as Vice President, Business Development. Prior to joining the Company, from December 2009 to June 2010, Mr. Piacquad was Principal of David A. Piacquad Consulting LLC. From March 2006 to December 2009, Mr. Piacquad served as Senior Vice President, Business Development and Licensing for ScheringPlough Corporationrationration. Prior to ScheringPlough, Mr. Piacquad served in a series of leadership roles in finance and business development at JJ, with his last position being Vice President, Ventures and Business Development.
Age: 59  President Since 2014      
805 447-1010  www.amgen.com

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Eric FainAbbott Laboratories
2017
Michael RousseauAbbott Laboratories
2017
Jonathon KellermanAllergan plc
2014
Shannon HallBio Rad Laboratories Inc
2014
Camille FarhatEndo International plc
2012
Thomas FrinziAbbott Laboratories
2016
John HertiaBio Rad Laboratories Inc
2014
Michael CrowleyBio Rad Laboratories Inc
2014
Ian SmithVertex Pharmaceuticals Incorpor
2017
Charles FoltzAbbott Laboratories
2013
Michael WarmuthAbbott Laboratories
2012
Scott WhiteAbbott Laboratories
2013
Daniel SalvadoriAbbott Laboratories
2014
Jaime ContrerasAbbott Laboratories
2013
Amit SachdevVertex Pharmaceuticals Incorpor
2017
J WhiteAbbott Laboratories
2013
Heather MasonAbbott Laboratories
2015
Timothy ErnstBio Rad Laboratories Inc
2016
Stephen FussellAbbott Laboratories
2013
William MeuryAllergan plc
2016
JeanYves PaveeAbbott Laboratories
2015

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators